Question 1

What is Tradjenta?

Accepted Answer

Tradjenta helps regulate blood glucose levels by influencing the body's natural insulin response. It works by increasing the levels of certain natural substances that lower blood sugar when it is high.

This process involves stimulating the pancreas to produce more insulin after eating and signaling the liver to stop producing excess sugar. By maintaining these levels, the medication assists in the overall management of glycemic control.

Question 2

What is Tradjenta used for?

Accepted Answer

Tradjenta is used to treat type 2 diabetes mellitus .

Question 3

How does Tradjenta work?

Accepted Answer

Mechanism of Action

Tradjenta belongs to a class of medications known as dipeptidyl peptidase-4 (DPP-4) inhibitors. It works by regulating the levels of natural substances in the body called incretins.

The Role of Incretins

Incretin hormones are released by the intestines throughout the day, and their levels increase significantly after eating a meal. These hormones help the body manage blood sugar in two primary ways:

Insulin Release: They signal the pancreas to produce and release more insulin when blood sugar levels are high.

Glucose Regulation: They signal the liver to decrease the amount of sugar (glucose) it produces.

How Tradjenta Works

In a typical metabolic process, an enzyme called DPP-4 quickly breaks down incretin hormones. Tradjenta works by blocking this enzyme, which prevents the rapid breakdown of incretins. By allowing these hormones to remain active in the bloodstream for a longer period, Tradjenta helps the body more effectively lower blood sugar levels after eating and maintains better glucose balance throughout the day.

Because Tradjenta works by enhancing the body's natural response to rising blood sugar, it is used specifically for type 2 diabetes. It is not used to treat type 1 diabetes or diabetic ketoacidosis, as these conditions involve different underlying mechanisms regarding insulin production.

Question 4

What are the active ingredients in Tradjenta?

Accepted Answer

The active ingredient in Tradjenta is linagliptin .

Question 5

What are the side effects of Tradjenta?

Accepted Answer

Common side effects of Tradjenta may include:

upper respiratory infection

nasopharyngitis

headache

Always consult with a healthcare professional about potential side effects.

Question 6

What drug class is Tradjenta?

Accepted Answer

Tradjenta belongs to the DPP-4 inhibitor drug class.

Question 7

What is the dosage of Tradjenta and how do I take it?

Accepted Answer

How to Take Tradjenta

Tradjenta is a tablet taken by mouth, usually once a day. It can be taken with or without food. It is important to take this medication exactly as directed by a healthcare provider and to follow the prescribed diet and exercise program.

Consistency and Timing

For the best results, try to take the medication at the same time each day. This helps maintain a steady amount of the drug in your system. Do not stop taking the medication or change your schedule without consulting a doctor, even if your blood sugar levels improve.

Missed Dose

If you miss a dose of Tradjenta, take it as soon as you remember. If it is nearly time for your next scheduled dose, skip the missed dose and resume your regular dosing schedule. Do not take two doses at the same time to make up for a missed one.

Question 8

Is Tradjenta safe during pregnancy and breastfeeding?

Accepted Answer

Pregnancy

Data regarding the use of Tradjenta in pregnant women are limited and insufficient to determine if there is a drug-associated risk for major birth defects or miscarriage. Animal studies have generally not shown significant risks to the fetus at doses similar to those used in humans, but these results do not always predict human response.

Healthcare providers emphasize that poorly controlled diabetes during pregnancy poses risks to both the mother and the fetus, including preeclampsia, pregnancy loss, and delivery complications. Patients who are pregnant or planning to become pregnant should consult their doctor to determine the most appropriate treatment plan for managing blood sugar.

Breastfeeding

It is currently unknown if Tradjenta is present in human breast milk, how it affects a breastfed infant, or its impact on milk production. Animal studies have shown that the medication is excreted in the milk of lactating rats.

When deciding whether to breastfeed while taking this medication, the health benefits of breastfeeding should be weighed against the mother's clinical need for the drug and any potential risks to the infant. A healthcare professional can help evaluate these factors based on individual circumstances.

Question 9

What forms and strengths does Tradjenta come in?

Accepted Answer

Tradjenta is supplied as a tablet for oral administration. The medication has the following physical characteristics:

Form: Film-coated tablet

Shape: Round and biconvex with beveled edges

Appearance: Light red in color with identifying debossing on the surface

Question 10

What is the FDA approval status of Tradjenta?

Accepted Answer

FDA Approval Status

Tradjenta, which contains the active ingredient linagliptin, was approved by the U.S. Food and Drug Administration (FDA) in May 2011. It belongs to a class of drugs called dipeptidyl peptidase-4 (DPP-4) inhibitors. It is indicated specifically for adults with type 2 diabetes and is not intended for the treatment of type 1 diabetes or diabetic ketoacidosis.

Safety Communications and Labeling Updates

The FDA has issued several safety communications and required label updates for the DPP-4 inhibitor class, including Tradjenta, based on post-marketing reports and clinical trials:

Heart Failure Risk: The FDA required updates to the drug labels for DPP-4 inhibitors to include a warning about the risk of heart failure. This risk may be higher in patients who already have heart or kidney disease.

Bullous Pemphigoid: The FDA identified a potential signal of risk for bullous pemphigoid, a skin condition that causes large, fluid-filled blisters. Labeling for Tradjenta includes information regarding this potential adverse reaction.

Severe Joint Pain: In 2015, the FDA warned that DPP-4 inhibitors might cause joint pain that can be severe and disabling. Patients are advised to contact their healthcare provider if they experience persistent or severe joint pain while taking the medication.

Boxed Warnings and REMS

Tradjenta does not currently carry any FDA boxed warnings, which are the most serious warnings used for significant safety risks. There is also no Risk Evaluation and Mitigation Strategy (REMS) program required for this medication.

Question 11

What should I know about Tradjenta and cost?

Accepted Answer

Insurance and Pharmacy Factors

The price of Tradjenta can vary based on your health insurance plan and its formulary. Your out-of-pocket costs are typically determined by your plan's co-pay or co-insurance requirements. Additionally, different pharmacies may offer varying retail prices for the medication.

Financial Assistance

Patients with commercial insurance may be eligible for manufacturer-sponsored savings cards or coupons to reduce their monthly costs. For those without insurance or with limited coverage, patient assistance programs may be available based on income and eligibility requirements.

Generic Availability

Tradjenta is a brand-name medication containing the active ingredient linagliptin. Generic versions are generally more affordable than brand-name drugs. You should speak with your pharmacist or healthcare provider to check for the current availability of generic linagliptin and how it might affect your treatment costs.

Tradjenta

Medication Quick Facts

📋Overview

What It's Used For

How It Works

Side Effects

Warnings & Precautions

Dosage & How to Take

Pregnancy & Breastfeeding

Forms & Strengths

FDA / Regulatory Status

Price Information

FAQ

Additional Resources

Support & Help Resources

Found an Error?